The science and structure of The Business of Longevity.

1. The strategic question

The defining executive question of the next decade is not how long you live. It is how long you lead at your best. Most senior leaders are still answering that question with a generic annual check-up, while their physiology decides the answer for them.

This paper is the working overview of how The Business of Longevity Academy answers the same question, for the same audience, in a structured cohort. It explains what we teach, why we teach it that way, and what you walk out with. It is written for two readers: a sitting executive deciding whether to apply, and the partner, board member, or sponsor she has to brief.

The argument has three parts. One. The physiology of sustained leadership is now a working science — five clinical windows that compound or compress healthspan in senior roles. Two. The decisive variable is not access to that science, which is widely published, but the quality of the filter you bring to it. Three. The most effective intervention is structured peer dialogue against a defended personal protocol, not another platform or product. The Academy exists to deliver all three.

2. Healthspan is the metric. Compression is the target.

Lifespan is the number of years you are alive. Healthspan is the number of years you are alive and functional — physically, cognitively, and professionally. The delta between the two is morbidity. For the average wealthy executive in the UK, that delta is currently ten to fifteen years.

If you have already won at career and capital, the strategic question is not how to add years at the end. It is how to push the morbidity window as late as possible, so your final decade is not spent compromised. The technical term for the goal is healthspan compression. Olshansky and colleagues called the public-health and economic argument for it the longevity dividend in 2006. Twenty years on, the empirical case is stronger, not weaker.

For a senior executive, three clinical windows decide most of the dividend:

• Cardiometabolic. The single biggest driver of premature mortality and cognitive decline. Modifiable, measurable, and routinely undermeasured by standard executive medicals.
• Cognitive architecture. Decision quality, working memory, attention span. Trainable, but more fragile under chronic stress than most leaders realise.
• Recovery capacity. The sleep-restoration loop and the autonomic nervous system that runs it. The variable that compounds fastest under role load.

For women in senior roles, two additional windows apply: hormonal transitions across perimenopause and post-menopause, and the sex-specific cardiometabolic curve that re-prices around the menopausal transition. These are the spine of the Female CEO Longevity programme.

3. The filter problem

The information environment around longevity is the worst it has ever been. The science is genuinely advancing — biological-age clocks, ApoB-LDL causality, GLP-1 metabolics, sleep-architecture wearables, hormonal-replacement re-analyses — and at the same time the marketing layer on top of it has become indistinguishable from religion. A senior leader who tries to read this field unaided will absorb a confident position on every nutrient, every protocol, every biomarker, and most of them will be wrong.

The most valuable thing the Academy teaches is not a fact set. It is the filter you apply to facts. Specifically:

• Strong evidence vs. emerging practice. Where the literature has converged across multiple high-quality studies, vs. where it is one mouse trial and a clinic's marketing department.
• Surrogate vs. clinical endpoints. Whether a marker actually predicts the outcome you care about, or only correlates with it under selected conditions.
• Effect size in absolute terms. The discipline of reading "a 30% reduction" and immediately asking 30% of what baseline rate, over what time, in what population.
• Cohort applicability. Whether a study population's age, sex, ancestry, and metabolic baseline applies to your physiology — or doesn't.

By Module 3, participants are reading published trials with the same instinct they bring to a board paper. That is the irreversible skill the programme builds.

4. The Method: Audit. Architect. Activate.

Every Academy programme follows the same arc. It is not designed for variety. It is designed to compound.

The Method is the same on both flagship programmes. The clinical content differs (CEO Lifespan is sex-neutral; Female CEO Longevity is sex-specific) but the arc is identical because the arc is what compounds.

5. Cohort, not platform

The Academy is not a content library. It is a 25-person cohort delivered live. The decision to cap each cohort at 25 is deliberate. Peer dynamics degrade above that number. We have seen it run sufficiently many times to believe the constraint.

What this means in practice:

• Live, weekly, on a fixed calendar. Six to thirteen weeks depending on the programme. Ninety minutes per session for CEO Lifespan, two hours for Female CEO Longevity.
• Cameras on. Peer breakouts. Pre-work that earns the live time. Sessions are not lectures with a passive audience.
• Accountability pair matched in Module 1. One named peer who knows your goals, sees your stuck points, and has agreed to push you.
• Alumni network that keeps running after graduation. Quarterly check-ins, an ongoing channel, returning faculty office hours.

If you only want the content, the literature is open and we will tell you where to start reading. If you want the protocol, that takes the cohort.

6. The faculty problem — and how we address it

Most executive longevity programmes are taught either by physicians without operating experience, or by operators without clinical fluency. Both lose the audience for different reasons. The Academy is co-led on purpose:

Guest faculty rotate per module: clinicians for the clinical content, operators for the leadership content. The structure means no single session is delivered by a voice that cannot hold both registers.

7. Pricing, format, and who this is for

The programmes are priced for senior executives invoicing through their company as a leadership-development expense, or paying personally as a strategic investment in their own runway. The fee reflects a 25-person cohort with named faculty and a personalised playbook — not a generic content library.

• CEO Lifespan — six modules, weekly live, GBP 4,000. Sitting CEOs and C-suite. Sex-neutral.
• Female CEO Longevity — thirteen modules across three phases, weekly live. Sitting CEOs, founders, partners, C-suite. Female-physiology specific. Includes the perimenopause / HRT decision-literacy modules.

Both are application-only. We review every application personally to ensure cohort balance and stage. We reply within five business days.

8. Frequently asked, briefly

Do I need to have had labs done first?

No. The programme assumes most participants have not. Module 1 walks you through the specific markers worth measuring and how to interpret them. Many participants order their first proper panel during the cohort.

What if I miss a session?

All live sessions are recorded and posted within 24 hours. Missed sessions are recoverable; missed peer dialogue is the cost — live attendance is strongly preferred.

What makes this different from a longevity clinic membership?

A clinic sells you tests, supplements, and consultations. This programme teaches you what to actually measure, what the evidence says, what your data means in your role, and how to build a sustainable protocol you can run for ten years. You walk out with judgement, not a subscription.

How private is my health data?

Your physiological data stays with you. The platform does not store health markers. The cohort never sees specifics — only the patterns you choose to share. Privacy is a feature, not a footnote, for senior leaders.

9. What happens next

If you have read this far and the framing fits, apply. The form is five minutes. We read every application personally. We reply within five business days — an offer, a request for a short conversation, or an honest no.

If you are inside a company and want to brief HR, your CFO, or a peer on the Academy as a leadership-development line item, this paper is the artefact to share. Send it on as is, or write to hello@expand.health and we will support the conversation.